Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer
Tori Wilhoit, J. Morrison Patrick, Megan Brafford May
Abstract
-mutated breast cancer who have progressed on endocrine therapy. This drug review will discuss the pharmacology of alpelisib, current data supporting its place in therapy, management of adverse events, and the clinical implications for advanced practitioners treating patients with HR-positive, HER2-negative breast cancer.
Topics & Concepts
MedicineMetastatic breast cancerOncologyBreast cancerInternal medicineCancerPI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer TherapiesCancer Treatment and Pharmacology